The invention relates to O-quinone compounds of general formula (I) as agents neutralising nitric oxide, and to the therapeutic or cosmetic use thereof.

##STR00001##

The invention relates to O-quinone compounds of general formula (I) as agents neutralising nitric oxide, and to the therapeutic or cosmetic use thereof.

##STR00001##

Biochemical scaffolds for regulating mammalian cell function. The biochemical scaffolds include a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and/or neurotransmitter modulator. The vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to harmonic oscillation for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by the liquid medium, and, when the biochemical scaffolds are delivered to and, thus, in communication with biological tissue, the biochemical scaffolds induce specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof.

Biochemical scaffolds for regulating mammalian cell function. The biochemical scaffolds include a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and/or neurotransmitter modulator. The vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to harmonic oscillation for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by the liquid medium, and, when the biochemical scaffolds are delivered to and, thus, in communication with biological tissue, the biochemical scaffolds induce specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof.

Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth, wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth, wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

A method of improving microbiome within an animal can comprise administering to the animal a composition comprising a probiotic and psyllium, wherein the probiotic comprises at least one of any suitable strain or subspecies of Enterococcus. Compositions containing a probiotic and psyllium are also provided herein.

A method of improving microbiome within an animal can comprise administering to the animal a composition comprising a probiotic and psyllium, wherein the probiotic comprises at least one of any suitable strain or subspecies of Enterococcus. Compositions containing a probiotic and psyllium are also provided herein.

A soft chewable composition containing psyllium. The soft chewable composition can have from about 1% to about 55% psyllium and have a Hardness Parameter of greater than about 300 gf at a water activity of about 0.80 and less than about 10,000 gf at a water activity of about 0.50 as measured by the Texture Profile Analysis Method.

A soft chewable composition containing psyllium. The soft chewable composition can have from about 1% to about 55% psyllium and have a Hardness Parameter of greater than about 300 gf at a water activity of about 0.80 and less than about 10,000 gf at a water activity of about 0.50 as measured by the Texture Profile Analysis Method.